xalkori (▼) 250 mg/1 kapsula kapsula, tvrda
pfizer bh d.o.o. sarajevo - crizotinib - kapsula, tvrda - 250 mg/1 kapsula - 1 kapsula, tvrda sadrži: 250 mg krizotiniba
memantine lek
pharmathen s.a. - memantin hidroklorid - alzheimerova bolest - psychoanaleptics i drugih anti-demencije lijekovi - liječenje bolesnika s umjerenom ili teškom alzheimerovom bolesti.
kisqali
novartis europharm limited - ribociklib sukcinata - neoplazme dojki - antineoplastična sredstva - kisqali je indiciran za liječenje žena s hormon receptor (h)‑pozitivan, людское эпидермическое ako uređaj primatelja 2 faktor rasta (her2)‑negativan lokalno-uobičajena ili metastatskih tumora dojke u kombinaciji s inhibitor aromataze, ili fulvestrant kao izvor endokrine terapije na temelju ili u žene koje su primili do hormonske terapije. u pre‑ ili perimenopauzi, endokrini terapija mora biti u kombinaciji s luteinizirajućeg hormona releasing hormon (lhrh) agonist.
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinom, squamous cell - antineoplastična sredstva - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
ask lek 100 mg/1 tableta tableta
novartis ba d.o.o. - acetilsalicilna kiselina - tableta - 100 mg/1 tableta - 1 tableta sadrži: 100 mg acetilsalicilne kiseline
xarelto (▼) 20 mg/1 tableta film tableta
bayer d.o.o. sarajevo - rivaroksaban - film tableta - 20 mg/1 tableta - 1 film tableta sadrži: 20 mg rivaroksaban
xarelto (▼) 15 mg/1 tableta film tableta
bayer d.o.o. sarajevo - rivaroksaban - film tableta - 15 mg/1 tableta - 1 film tableta sadrži: 15 mg rivaroksaban
glucobay 50 mg 50 mg/1 tableta tableta
bayer d.o.o. sarajevo - akarboza - tableta - 50 mg/1 tableta - 1 tableta sadrži: 50 mg akarboza
ultravist300 otopina za injekciju ili otopina za infuziju ili oralna otopina 623.4 mg/1 ml otopina za injekciju/ infuziju
bayer d.o.o. sarajevo - jopromid - otopina za injekciju/ infuziju - 623.4 mg/1 ml - 1 ml otopine za injekciju/infuziju sadrži: 623,40 mg jopromida (što odgovara 300 mg joda)
ultravist300 otopina za injekciju ili otopina za infuziju ili oralna otopina 623.4 mg/1 ml otopina za injekciju/ infuziju
bayer d.o.o. sarajevo - jopromid - otopina za injekciju/ infuziju - 623.4 mg/1 ml - 1 ml otopine za injekciju/infuziju sadrži: 623,40 mg jopromida (što odgovara 300 mg joda)